State Street’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,844,990
| Closed | -$275M | – | 4183 |
|
|
2026
Q1 | $275M | Buy |
6,844,990
+2,231,544
| +48% | +$48.1M | 0.01% | 793 |
|
|
2025
Q4 | $116M | Buy |
4,613,446
+575,802
| +14% | +$13.5M | ﹤0.01% | 1271 |
|
|
2025
Q3 | $91.4M | Buy |
4,037,644
+474,923
| +13% | +$11.1M | ﹤0.01% | 1378 |
|
|
2025
Q2 | $61.7M | Sell |
3,562,721
-378,684
| -10% | -$7.01M | ﹤0.01% | 1574 |
|
|
2025
Q1 | $86.2M | Sell |
3,941,405
-583,750
| -13% | -$16.1M | ﹤0.01% | 1347 |
|
|
2024
Q4 | $144M | Buy |
4,525,155
+484,294
| +12% | +$14.6M | 0.01% | 1122 |
|
|
2024
Q3 | $117M | Sell |
4,040,861
-105,833
| -3% | -$3.92M | ﹤0.01% | 1238 |
|
|
2024
Q2 | $159M | Buy |
4,146,694
+1,237,166
| +43% | +$56M | 0.01% | 993 |
|
|
2024
Q1 | $171M | Sell |
2,909,528
-5,894
| -0.2% | -$376K | 0.01% | 962 |
|
|
2023
Q4 | $175M | Sell |
2,915,422
-322,692
| -10% | -$16.4M | 0.01% | 926 |
|
|
2023
Q3 | $123M | Buy |
3,238,114
+955,029
| +42% | +$42M | 0.01% | 1044 |
|
|
2023
Q2 | $208M | Sell |
2,283,085
-696,777
| -23% | -$60.1M | 0.01% | 777 |
|
|
2023
Q1 | $197M | Sell |
2,979,862
-492,052
| -14% | -$28.4M | 0.01% | 779 |
|
|
2022
Q4 | $180M | Buy |
3,471,914
+514,641
| +17% | +$27.3M | 0.01% | 810 |
|
|
2022
Q3 | $202M | Sell |
2,957,273
-539,652
| -15% | -$31.9M | 0.01% | 728 |
|
|
2022
Q2 | $158M | Buy |
3,496,925
+590,469
| +20% | +$26.9M | 0.01% | 865 |
|
|
2022
Q1 | $148M | Buy |
2,906,456
+187,088
| +7% | +$8.26M | 0.01% | 1031 |
|
|
2021
Q4 | $129M | Sell |
2,719,368
-106,827
| -4% | -$4.21M | 0.01% | 1115 |
|
|
2021
Q3 | $93.2M | Buy |
2,826,195
+879,227
| +45% | +$49.4M | ﹤0.01% | 1321 |
|
|
2021
Q2 | $123M | Sell |
1,946,968
-251,605
| -11% | -$13M | 0.01% | 1143 |
|
|
2021
Q1 | $94.3M | Sell |
2,198,573
-232,180
| -10% | -$11M | 0.01% | 1274 |
|
|
2020
Q4 | $139M | Sell |
2,430,753
-433,406
| -15% | -$18.3M | 0.01% | 920 |
|
|
2020
Q3 | $86.4M | Sell |
2,864,159
-82,655
| -3% | -$2.47M | 0.01% | 1063 |
|
|
2020
Q2 | $96.2M | Buy |
2,946,814
+448,050
| +18% | +$14.4M | 0.01% | 990 |
|
|
2020
Q1 | $66.9M | Buy |
2,498,764
+199,529
| +9% | +$7.08M | 0.01% | 1068 |
|
|
2019
Q4 | $70.4M | Buy |
2,299,235
+746,678
| +48% | +$20.7M | ﹤0.01% | 1289 |
|
|
2019
Q3 | $37.4M | Sell |
1,552,557
-142,765
| -8% | -$3.93M | ﹤0.01% | 1644 |
|
|
2019
Q2 | $43M | Buy |
1,695,322
+625,979
| +59% | +$12.7M | ﹤0.01% | 1580 |
|
|
2019
Q1 | $20.9M | Buy |
1,069,343
+4,316
| +0.4% | +$67.9K | ﹤0.01% | 2011 |
|
|
2018
Q4 | $14M | Sell |
1,065,027
-299,238
| -22% | -$4.59M | ﹤0.01% | 2231 |
|
|
2018
Q3 | $24.3M | Buy |
1,364,265
+156,061
| +13% | +$2.88M | ﹤0.01% | 2049 |
|
|
2018
Q2 | $26.6M | Buy |
1,208,204
+1,037,258
| +607% | +$23.8M | ﹤0.01% | 1933 |
|
|
2018
Q1 | $3.78M | Buy |
170,946
+75,000
| +78% | +$1.47M | ﹤0.01% | 2924 |
|
|
2017
Q4 | $2.08M | Buy |
+95,946
| New | +$1.41M | ﹤0.01% | 3171 |
|
Other funds holding APLS
State Street's APLS Position: Q2 2026 in Review
State Street sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,844,990 shares — an estimated $275M sold.
State Street first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $275M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- State Street reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- State Street sold 6,844,990 Apellis Pharmaceuticals shares in Q2 2026, an estimated $275M.
- State Street first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- State Street's Apellis Pharmaceuticals position peaked at $275M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.